Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

6 Oct 2016 11:43

RNS Number : 8959L
PuriCore Plc
06 October 2016
 

 

PuriCore plc

("PuriCore" or the "Company")

 

Result of General Meeting

 

 

6 October 2016 - PuriCore plc (AIM: PURI), the emerging specialty biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, announced on 20 September 2016 it had agreed to sell the Group's Supermarket Retail Business, subject to Shareholder approval and other customary requirements, to Chemstar Corp.

 

The Company is pleased to announce that the Resolution, as set out in the notice of general meeting contained within the Circular to Shareholders, approving the Disposal was duly passed at the general meeting held today. Completion of the Disposal is expected tomorrow and a further announcement will be made in due course.

 

Enquiries:

 

PuriCore plc

+44 (0) 20 3727 1000

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

FTI Consulting

+44 (0) 20 3727 1000

Simon Conway / Mo Noonan

N+1 Singer (Nominated Adviser and Broker)

+44 (0) 20 7496 3000

Aubrey Powell / Jen Boorer

 

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014 (MAR).

 

Unless otherwise indicated, capitalised terms in this announcement have the same definition as in the Circular.

 

About PuriCore

 

PuriCore is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated a drug development programme, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes their formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas such as Dermatology, Ophthalmology and potentially rare diseases. For more details, go to the Company's website: www.puricore.com

 

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMDMMGGGVZGVZM
Date   Source Headline
2nd Nov 20097:00 amRNSDarren Weiss promoted to CFO & Executive Director
15th Sep 20099:47 amRNSHolding(s) in Company
2nd Sep 20092:32 pmRNSHolding(s) in Company
27th Aug 20097:00 amRNSTotal Voting Rights
25th Aug 20094:18 pmRNSHolding(s) in Company
25th Aug 20097:00 amRNSPuriCore New $2.1 Million Facility
25th Aug 20097:00 amRNSInterim Results
5th Aug 20097:00 amRNSTrading Statement
5th Aug 20097:00 amRNSAcquisition and Placing
4th Aug 20097:00 amRNSBlocklisting Interim Review
24th Jul 20094:40 pmRNSSecond Price Monitoring Extn
24th Jul 20094:35 pmRNSPrice Monitoring Extension
10th Jul 20094:40 pmRNSSecond Price Monitoring Extn
10th Jul 20094:35 pmRNSPrice Monitoring Extension
7th Jul 20094:40 pmRNSSecond Price Monitoring Extn
7th Jul 20094:35 pmRNSPrice Monitoring Extension
17th Jun 20097:00 amRNSPresenting at Piper Jaffray European Conference
5th Jun 200911:20 amRNSResult of AGM
28th May 20091:16 pmRNSUS retailer extends use of Sterilox systems
27th May 20097:00 amRNSAnnual Information Update
30th Apr 20095:01 pmRNSHolding(s) in Company
30th Apr 20097:00 amRNSSterilox Effective against Human/Animal Influenza
28th Apr 20097:01 amRNSQ1 Interim Management Statement
28th Apr 20097:00 amRNSFinal Results
17th Feb 200910:45 amRNSHolding(s) in Company
10th Feb 20094:28 pmRNSDirector/PDMR Shareholding
9th Feb 20097:00 amRNSDirector/PDMR Shareholding
6th Feb 200910:27 amRNSHolding(s) in Company
4th Feb 20099:28 amRNSBlocklisting Interim Review
3rd Feb 20099:41 amRNSDirector/PDMR Shareholding
2nd Feb 20097:00 amRNSTrading Statement
2nd Jan 20097:00 amRNSDirector/PDMR Shareholding
29th Dec 20084:34 pmRNSDirector/PDMR Shareholding
19th Dec 20084:43 pmRNSSecond Price Monitoring Extn
19th Dec 20084:36 pmRNSPrice Monitoring Extension
12th Nov 20085:01 pmRNSDirector/PDMR Shareholding
3rd Nov 20087:00 amRNSNotification of PDMR Interest - Option Award
24th Oct 20087:00 amRNSReceives an order from Safeway
13th Oct 20087:01 amRNSBoard and Organisational Changes
13th Oct 20087:00 amRNSInterim Management Statement
1st Oct 20087:00 amRNSRaises $9.74 million
11th Sep 20085:51 pmRNSHolding(s) in Company
4th Sep 20085:51 pmRNSHolding(s) in Company
3rd Sep 20085:26 pmRNSHolding(s) in Company
29th Aug 20082:44 pmRNSPDMR Dealings
29th Aug 20087:00 amRNSTotal Voting Rights
29th Aug 20087:00 amRNSInterim Results
26th Aug 20083:02 pmRNSResult of General Meeting
22nd Aug 20087:00 amRNSResult of Open Offer
4th Aug 20088:27 amRNSBlocklisting six monthly retu

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.